Skip to main content
PMC home page
Oncotarget logoLink to Oncotarget
. 2015 May 8;6(26):22970–22977. doi: 10.18632/oncotarget.4042

Association of the intermediate filament nestin with cancer stage: a meta-analysis based on 223 positive/high nestin cases and 460 negative/low case-free controls

Beilong Zhong 1,#, Tao Wang 2,3,#, Jianyong Zou 4,5,#, Fangfang Zheng 6, Rijiao Huang 7, Xiaobin Zheng 8, Weilin Yang 9, Zhenguang Chen 4,5,9,#
PMCID: PMC4673213  PMID: 26015397

Abstract

Background

Nestin, a member of the intermediate filament protein family, has been reported to be associated with several types of neoplastic transformation. However, questions remain, with studies reporting sometimes inconclusive or conflicting data. Thus, the aim of this study was to evaluate literature reports on the relationship between nestin and cancer stage.

Methods

Relevant articles published as of June 2014 were retrieved from multiple databases. After applying specific inclusion criteria, we chose seven articles relating to nestin expression and cancer stage, which included a total of 223 positive/high nestin cases and 460 negative/low case-free controls.

Results

Overall, positive/high nestin was significantly associated with median or advanced stages of several types of cancer (nestin and cancer stage: OR = 1.90, 95% CI = 1.30–2.78; nestin and lymph node: OR = 2.17, 95% CI = 1.26–3.72). Notably, studies relating to lung cancer (three qualifying articles) showed a significant association between nestin and lung cancer stage (OR = 2.00, 95% CI = 1.16–3.44).

Conclusion

These findings indicate that positive/high nestin may be more strongly linked to median or advanced cancer stage and correlated with malignant characteristics that lead to poor prognosis in different cancers, especially lung cancer.

Keywords: nestin, intermediate filament, cancer stage, TNM staging, meta-analysis

INTRODUCTION

Nestin, a member of the class VI intermediate filament protein family, is expressed in normal cells of different tissues and organs.[3] Nestin expression was first reported in progenitor cells of central and peripheral nervous systems.[4] Its expression has since been reported in skeletal and cardiac muscle progenitors, developing tooth buds, testis and hair follicle sheath progenitor cells of the skin, a distribution that suggests that nestin is a potential indicator of proliferative and multipotency status in several types of progenitor cells.[5, 6-11]

Recent reports have indicated that nestin might be linked to malignant characteristics, suggesting that abundant nestin expression correlates with greater malignancy and poorer prognosis in different cancers. Moreover, several studies have also reported that nestin is a marker of cancer stem cells in different malignancies, including brain tumors, uterine cancer, cervical cancer, prostate cancer, bladder cancer, head and neck cancer, ovarian cancer, testicular cancer, pancreatic cancer, and malignant rhabdoid tumors.[12-19]

The TNM (primary Tumor, lymph Nodes, and distant Metastasis) classification system, published by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) for Malignant Tumors, has been used worldwide and across all medical specialties as a cancer-staging technique.[1] The TNM system is based on the anatomic extent of the tumor, as determined clinically and, in most instances, histopathologically, and can facilitate diagnosis, prognosis, treatment and other clinical decisions. [1, 2]

Although several articles on the relationship between nestin and cancer stage have been reported, including Masao et al.,[20] Shinichiro et al.,[21] Chen et al.[22-23] and Karsten et al.[24], only that of Karsten et al. reported that high nestin was strongly, and significantly, associated with cancer stage. Because of the relatively small sample sizes and limited statistical power of these individual, inconclusive studies, it is important to summarize the results from different studies to more accurately assess the association of positive/high nestin with cancer stage. To this end, we carried out a meta-analysis of all eligible studies, combining results to produce a single estimate of the major effect with enhanced precision.[25] We further performed a subgroup analysis stratified according to lymph node involvement and cancer category.

RESULTS

Study characteristics

Our search strategy identified 150 potentially relevant studies. After checking the title and abstract, a total of 30 articles consistent with our search criteria were preliminarily chosen for further detailed evaluation. After careful screening, we excluded 16 studies because data were insufficient for analysis. Of the remaining 14 studies, seven did not focus on nestin and cancer staging. Ultimately, seven studies on nestin and cancer staging that included a total of 223 positive/high nestin cases and 460 negative/low case-free controls were deemed eligible for the final analysis. The characteristics of the included studies are listed in Table 1. All studies were related to clinical research, including three lung cancer studies, one pancreatic cancer study, one prostate cancer study, one gastric adenocarcinoma study, and one oral cancer study. All cancers were confirmed pathologically. The study selection process is shown schematically in Figure 1.

Table 1. Characteristics of the studies included in the meta-analysis.

First author Year Country Ethnicity Cancer type Total No. of patients Median age (years)
Masao 2009 Japan Asian PC 60 64.6
Karsten 2009 Norway Germanic Prostate cancer 104 62.0
Chen 2010 China Asian Lung cancer 52 58.2
Shinichiro 2010 Japan Asian Lung cancer 171 64
Sadhna 2011 USA Caucasian GA 159 63
Mascolo 2012 Italy Germanic Oral cancer 66 60.5
Chen 2014 China Asian Lung cancer 71 57.6
Open in a new tab

PC, pancreatic cancer; GA, gastric adenocarcinoma.

Figure 1. Flow chart of study selection.

Figure 1

Open in a new tab

Meta-analysis results

The frequency of tumors, lymph node involvement, and cancer stage in positive/high and negative/low nestin patients are shown in detail in Table 2. All TNM staging data were collected, and a subset of lymph node data was extracted.

Seven articles that included a total of 223 cases and 460 controls were used to evaluate the relationship between nestin with cancer stage. The main results of this meta-analysis are indicated in Figure 2. Overall, there was evidence for an association between positive/high nestin and median/advanced cancer stage in different cancers when all eligible studies were pooled into the meta-analysis. As show in Figure 2, the significant main effect observed was for nestin and median/advanced cancer stage (positive/high nestin vs. negative/low nestin: OR = 1.90, 95% CI = 1.30–2.78, P = 0.0009).

Figure 2. Forest plots of nestin and median/advanced cancer stage among all cases (positive/high nestin vs. negative/low nestin).

Figure 2

Open in a new tab

The squares and horizontal lines correspond to the study-specific OR and 95% CI, respectively. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.

Four articles that included 110 cases and 277 controls were used to evaluate the relationship between nestin and lymph node involvement. In the analysis stratified by lymph node involvement (N1-2 vs. N0), as shown in Figure 4, the main effect remained (positive/high nestin vs. negative/low nestin: OR = 2.17, 95% CI = 1.26–3.72, P = 0.005). For the analysis stratified by cancer category, three articles that included 87 cases and 207 controls were used to evaluate the relationship between nestin and lung cancer (median or advanced stage vs. early stage). As show in Figure 5, the main effect remained in studies of lung cancer (positive/high nestin vs. negative/low nestin: OR = 2.00, 95% CI = 1.16–3.44, P = 0.01).

Figure 4. Forest plots of nestin and lymph node involvement among all cases (N1-2 vs. N0).

Figure 4

Open in a new tab

The squares and horizontal lines correspond to the study-specific OR and 95% CI, respectively. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.

Figure 5. Forest plots of nestin and lung cancer stage in three cases (median or advanced stage vs. early stage).

Figure 5

Open in a new tab

The squares and horizontal lines correspond to the study-specific OR and 95% CI, respectively. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.

More importantly, regarding to focus at the association of nestin with lung cancer staging, as shown in Figure 6, we have done some analysis on the relationship between nestin and T staging or N staging. In the analysis stratified by T staging (T3-4 vs. T1-2) in lung cancer, the main effect remained (positive/high nestin vs. negative/low nestin: OR = 3.73, 95% CI = 1.42–9.74, P = 0.007). Meanwhile, in the analysis stratified by N staging (N1-2 vs. N0) in lung cancer, the main effect remained (positive/high nestin vs. negative/low nestin: OR = 2.73, 95% CI = 1.39–5.37, P = 0.004).

Figure 6.

Figure 6

Open in a new tab

A. Forest plots of nestin and T staging of lung cancer in two cases (T3-4 vs. T1-2). B. Forest plots of nestin and N staging of lung cancer in two cases (N1-2 vs. N0). The squares and horizontal lines correspond to the study specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.

Tests of heterogeneity

Tests of heterogeneity between trials using the Q statistic showed no significant heterogeneity in the following analyses: nestin expression with cancer staging (positive/high nestin vs. negative/low nestin, P = 0.76, I2 = 0%), nestin expression with lymph node positivity (positive/high nestin vs. negative/low nestin (P = 0.67, I2 = 0%), and nestin expression with lung cancer stage, positive/high nestin vs. negative/low nestin (P = 0.98, I2 = 0%). Accordingly, data were analyzed using a fixed-effects model.]

Publication bias

Funnel plots were performed to assess publication bias. As show in Figure 3, the funnel plots revealed no obvious asymmetry at any cancer stage (median or advanced stage vs. early stage), and the results revealed no publication bias (P > 0.05).

Figure 3. Funnel plot assessing evidence of publication bias from seven studies (median or advanced stage vs. early stage).

Figure 3

Open in a new tab

DISCUSSION

TNM stage is determined according to the outcomes of physical examination, biopsy, and imaging tests; in clinical application, a pathological report is the basis of TNM staging.[27] In addition to anatomic tumor categories, most sites and tumor types are classified according to TNM stage, with the anatomic extent of the tumor determining the cancer stage.[1, 2] Clearly distinguishing between stages and reliably estimating survival probability require that each stage be homogeneous. Stages I to III correspond to progressively advanced localized and regional cancer, whereas stage IV corresponds to systemic metastases. An accurate staging system is important for guiding physicians in treatment options and determining patients' prognosis.[28]

Nestin was initially discovered based on its expression in neural progenitor cells, where it was considered a marker for distinguishing precursor cells from differentiated cells.[29, 30] Subsequent reports have shown that nestin is expressed in breast, prostate and pancreatic cancer, and is positively correlated with tumor malignancy.[31-33] But some findings regarding nestin are inconclusive or controversial, especially in the context of cancer staging.

Although a number of studies investigating the association of nestin with cancer stage have been reported, only one clinical study by Karsten et al. demonstrated a significant relationship between high nestin levels and cancer stage.[24] Our aim here was to clarify the relationship between nestin and cancer stage by performing a meta-analysis of the literature in the field. This analysis provided evidence of an association between positive/high nestin and median/advanced cancer stage in different cancers, demonstrating a significant main effect of positive/high nestin versus negative/low nestin. Analyses of nestin association stratified according to lymph node involvement (N1-2 vs. N0) and cancer category were also statistically significant.

The relationships established here suggest that positive/high nestin can be used as an added factor in determining TNM stage and judging cancer malignancy, especially for lung cancer. Regarding to focus at the association of nestin with lung cancer staging, we have done some analysis on the relationship between nestin and T staging or N staging. Analyses of nestin association stratified according to T staging (T3-4 vs. T1-2) or N staging (N1-2 vs. N0) and lung cancer category were also statistically significant. This analysis provided evidence of an association between positive/high nestin and median/advanced cancer stage in lung cancer, demonstrating a significant main effect of positive/high nestin versus negative/low nestin. Further investigations of nestin and lung cancer stage on a larger scale are needed to verify this result and firmly establish nestin as a cancer malignancy biomarker.

Some limitations of this meta-analysis should be noted. Firstly, this meta-analysis was based on pooled positive or high nestin data; thus, we were only able to address the relationship between positive/high nestin and cancer stage, and not individual positive or high-nestin values. Secondly, a small-study effect, in which results reported in smaller studies have a disproportionate effect on the final analysis, could not be avoided because of the relatively small size of some of the studies. Ultimately, additional large scale-studies with more detailed individual data are warranted to further validate the relationship of nestin with cancer stage.

CONCLUSIONS

In summary, our meta-analysis provides evidence of an association between positive/high nestin and cancer stage, suggesting that knowledge of nestin expression status could facilitate cancer staging, especially in lung cancer.

MATERIALS AND METHODS

Publication search

Relevant articles published as of June 2014 were retrieved from multiple databases, including PubMed, ISI Web of Knowledge, Embase, and the Chinese National Knowledge Infrastructure (CNKI) using the keywords nestin, malignancy, neoplasm, cancer staging and TNM staging. Articles with case-control or cohort studies related to the association of positive/high nestin and cancer staging were collected.

Inclusion criteria

The following criteria were used to select publications for further meta-analysis: (1) published in English or Chinese, regardless of publication date; (2) evaluated associations between positive/high nestin and cancer stage; (3) confirmed cancer patients pathologically; (4) included detailed cancer/TNM staging data; and (5) contained at least two comparison groups (positive-nestin group vs. negative-nestin group, or high-nestin group vs. low-nestin group).

Data collection

Publication details such as the first author's name, publication year, patients' country of origin and ethnicity, total number of patients, cancer type, median/mean age of the study population, and disease stage were collected for each eligible publication. Positive or high nestin and cancer/TNM stage were end points of interest.

Statistical analysis

Patients were divided into positive/high nestin and negative/low nestin groups, and the associations between positive/high nestin and cancer stage were measured by determining odds ratios (ORs) with 95% confidence intervals (CIs). The significance of pooled ORs was determined by the Z test. Statistical heterogeneity among studies was assessed using Q and I2 statistics, where variation due to heterogeneity or random error identified with Q tests were further defined according to I2 values, as follows: I2 = 0–25%, no heterogeneity; I2 = 25–50%, moderate heterogeneity; I2 = 50–75%: large heterogeneity; and I2 = 75–100%, extreme heterogeneity.[26] A fixed-effects model was applied in the initial analysis, and if significant heterogeneity existed, a confirmed random-effects model was used. Publication bias was evaluated using funnel plots. All statistical analyses were carried out with Review Manager version 5.0 (Revman; The Cochrane Collaboration, Oxford, UK). All P-values in the meta-analysis were two-sided, and a P-value < 0.05 was considered significant.

Acknowledgments

This study was supported by grants from the National Natural Science Foundation of China (No. 81101774).

Footnotes

COMPETING INTERESTS

The authors declare that they have no competing interests.

Authors' contributions

BZ, TW, and ZG conceived and designed the study, and participated in selecting literature reports, extracting data, performing statistical analyses and drafting the manuscript. JZ, FZ, RH, XZ, and WY were involved in critically assessing and revising the intellectual content of the manuscript. All authors read and approved the final manuscript.

REFERENCES

  • 1.Sobin LH. TNM: evolution and relation to other prognostic factors. Semin Surg Oncol. 2003;21:3–7. doi: 10.1002/ssu.10014. [DOI] [PubMed] [Google Scholar]
  • 2.TNM Classification of Malignant Tumors. 5. Wiley; New York: 1997. [Google Scholar]
  • 3.Guérette D, Khan PA, Savard PE, Vincent M. “Molecular evolution of type VI intermediate filament proteins”. BMC Evol Biol. 2007;7:164. doi: 10.1186/1471-2148-7-164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Cattaneo E, McKay R. Proliferation and differentiation of neuronal stem cells regulated by nerve growth factor. Nature. 1990;347:762–765. doi: 10.1038/347762a0. [DOI] [PubMed] [Google Scholar]
  • 5.Lendahl U, Zimmerman LB, McKay RD. CNS stem cells express a new class of intermediate filament protein. Cell. 1990;60:585–595. doi: 10.1016/0092-8674(90)90662-x. [DOI] [PubMed] [Google Scholar]
  • 6.Park D, Xiang AP, Mao FF, Zhang L, Di CG, Liu XM, Shao Y, Ma BF, Lee JH, Ha KS, Walton N, Lahn BT. Nestin is required for the proper self-renewal of neural stem cells. Stem Cells. 2010;28:2162–2171. doi: 10.1002/stem.541. [DOI] [PubMed] [Google Scholar]
  • 7.Shimizu T, Sugawara K, Tosaka M, Imai H, Hoya K, Takeuchi T, Sasaki T, Saito N. Nestin expression in vascular malformations: a novel marker for proliferate endothelium. Neurol Med Chir(Tokyo) 2006;46:111–117. doi: 10.2176/nmc.46.111. [DOI] [PubMed] [Google Scholar]
  • 8.Takakuwa O, Maeno K, Kunii E, Ozasa H, Hijikata H, Uemura T, Kasai D, Ohkubo H, Miyazaki M, Oguri T, Niimi A. Involvement of intermediate filament nestin in cell growth of small-cell lung cancer. Lung cancer. 2013;81:174–179. doi: 10.1016/j.lungcan.2013.04.022. [DOI] [PubMed] [Google Scholar]
  • 9.Amoh Y, Yang M, Li L, Reynoso J, Bouvet M, Moossa AR, Katsuoka K, Hoffman RM. Nestin-linked green fluorescent protein transgenic nude mouse for imaging human tumor angiogenesis. Cancer Res. 2005;65:5352–5357. doi: 10.1158/0008-5472.CAN-05-0821. [DOI] [PubMed] [Google Scholar]
  • 10.Xue XJ, Yuan XB. Nestin is essential for mitogen-stimulated proliferation of neural progenitor cells. Mol Cell Neurosci. 2010;45:26–36. doi: 10.1016/j.mcn.2010.05.006. [DOI] [PubMed] [Google Scholar]
  • 11.Krüger K, Stefansson I.M, Collett K, Arnes J.B, Aas T, Akslen L.A. Microvessel proliferation by co-expression of endothelial nestin and Ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer. Breast. 2013;22:282–288. doi: 10.1016/j.breast.2012.07.008. [DOI] [PubMed] [Google Scholar]
  • 12.Jimeno A, Feldmann G, Suárez-Gauthier A, Rasheed Z, Solomon A, Zou GM, Rubio-Viqueira B, García-García E, López-Ríos F, Matsui W, Maitra A, Hidalgo M. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther. 2009;8:310–314. doi: 10.1158/1535-7163.MCT-08-0924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Bentivegna A, Conconi D, Panzeri E, Sala E, Bovo G, Viganò P, Brunelli S, Bossi M, Tredici G, Strada G, Dalprà L. Biological heterogeneity of putative bladder cancer stem-like cell populations from human bladder transitional cell carcinoma samples. Cancer Sci. 2010;101:416–424. doi: 10.1111/j.1349-7006.2009.01414.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene. 2004;23:7267–7273. doi: 10.1038/sj.onc.1207946. [DOI] [PubMed] [Google Scholar]
  • 15.Bortolomai I, Canevari S, Facetti I, De Cecco L, Castellano G, Zacchetti A, Alison MR, Miotti S. Tumor initiating cells: Development and critical characterization of a model derived from the A431 carcinoma cell line forming spheres in suspension. Cell Cycle. 2010;9:1194–1206. doi: 10.4161/cc.9.6.11108. [DOI] [PubMed] [Google Scholar]
  • 16.Okuno K, Ohta S, Kato H, Taga T, Sugita K, Takeuchi Y. Expression of neural stem cell markers in malignant rhabdoid tumor cell lines. Oncol Rep. 2010;23:485–492. [PubMed] [Google Scholar]
  • 17.Hombach-Klonisch S, Paranjothy T, Wiechec E, Pocar P, Mustafa T, Seifert A, Zahl C, Gerlach KL, Biermann K, Steger K, Hoang-Vu C, Schulze-Osthoff K, Los M. Cancer stem cells as targets for cancer therapy: selected cancers as examples. Arch Immunol Ther Exp (Warsz) 2008;56:165–180. doi: 10.1007/s00005-008-0023-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Kasper S. Exploring the origins of the normal prostate and prostate cancer stem cell. Stem Cell Rev. 2008;4:193–201. doi: 10.1007/s12015-008-9033-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Guzmán-Ramírez N, Völler M, Wetterwald A, Germann M, Cross NA, Rentsch CA, Schalken J, Thalmann GN, Cecchini MG. In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. Prostate. 2009;69:1683–1693. doi: 10.1002/pros.21018. [DOI] [PubMed] [Google Scholar]
  • 20.Kawamoto M, Ishiwata T, Cho K, Uchida E, Korc M, Naito Z, Tajiri T. Nestin expression correlates with nerve and retroperitoneal tissue invasion in pancreatic cancer. Hum Pathol. 2009;40:189–198. doi: 10.1016/j.humpath.2008.02.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Ryuge S, Sato Y, Wang G, Matsumoto T, Jiang S, Katono K, Inoue H, Satoh Y, Masuda N. Prognostic significance of Nestin expression in resected non-small cell lung cancer. Chest. 2011;139:862–869. doi: 10.1378/chest.10-1121. [DOI] [PubMed] [Google Scholar]
  • 22.Chen Z, Wang T, Luo H, Lai Y, Yang X, Li F, Lei Y, Su C, Zhang X, Lahn BT, Xiang AP. Expression of nestin in lymph node metastasis and lymphangiogenesis in non-small cell lung cancer patients. Human Pathology. 2010;41:737–744. doi: 10.1016/j.humpath.2009.10.018. [DOI] [PubMed] [Google Scholar]
  • 23.Chen Z, Wang J, Cai L, Zhong B, Luo H, Hao Y, Yu W, Wang B, Su C, Lei Y, Bella AE, Xiang AP, Wang T. Role of the stem cell-associated intermediate filament Nestin in malignant proliferation of non-small cell lung cancer. PloS ONE. 9:e85584. doi: 10.1371/journal.pone.0085584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate pancer. Cancer Res. 2009;69:4708–4715. doi: 10.1158/0008-5472.CAN-08-4417. [DOI] [PubMed] [Google Scholar]
  • 25.Zhao Y, Han Y, Zhang L, Wang Y, Ma Y, Zhang F, Fu D, Wang X. Quantitative assessment of the effect of cytochrome P450 2C9 gene polymorphism and colorectal cancer. PLoS ONE. 2013;8:e60607. doi: 10.1371/journal.pone.0060607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560. doi: 10.1136/bmj.327.7414.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Society AC: AJCC Cancer Staging Manual-Fifth Edition Lippincott-Raven. 1997 [Google Scholar]
  • 28.Wallin E, Heijne GV. Genome-wide analysis of integral membrane proteins from eubacterial, archaean, and eukaryotic organisms. Protein Sci. 1998;7:1029–1038. doi: 10.1002/pro.5560070420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Carter JH, Douglass LE, Deddens JA, Colligan BM, Bhatt TR, Pemberton JO, Konicek S, Hom J, Marshall M, Graff JR. Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res. 2004;10:3448–3456. doi: 10.1158/1078-0432.CCR-03-0210. [DOI] [PubMed] [Google Scholar]
  • 30.Wang Q, Zeng YJ, Huo P, Hu JL, Zhang JH. A specialized plug-in software module for computer-aided quantitative measurement of medical images. Med Eng Phys. 2003;25:887–892. doi: 10.1016/s1350-4533(03)00114-0. [DOI] [PubMed] [Google Scholar]
  • 31.Ohike N, Sato M, Hisayuki T, Imataka H, Sato S, Wada Y, Saito K, Takahashi M, Tajiri T, Kunimura T, Morohoshi T. Immunohistochemical analysis of Nestin and c-kit and their significance in pancreatic tumors. Pathol Int. 2007;57:589–593. doi: 10.1111/j.1440-1827.2007.02143.x. [DOI] [PubMed] [Google Scholar]
  • 32.Wiese C, Rolletschek A, Kania G, Blyszczuk P, Tarasov KV, Tarasova Y, Wersto RP, Boheler KR, Wobus AM. Nestin expression: a property of multi-lineage progenitor cells? Cell Mol Life Sci. 2004;61:2510–2522. doi: 10.1007/s00018-004-4144-6. [DOI] [PubMed] [Google Scholar]
  • 33.Suzuki S, Namiki J, Shibata S, Mastuzaki Y, Okano H. The neural stem/progenitor cell marker nestin is expressed in proliferative endothelial cells, but not in mature vasculature. J Histochem Cytochem. 2010;58:721–730. doi: 10.1369/jhc.2010.955609. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES